SPEAKERS:
Elizabeth Arnold, Vice President, Brand Lead, Bristol Myers Squibb
Chris Edmonds, Global Price and Market Access Director, AstraZeneca
Evan Reddick, Medical Head of Leukemia, MDS, MF, Takeda
Nataliya Andreychuk, Co-Founder and Chief Executive Officer, Viseven
KEY TAKEAWAYS:
• Late life cycle brands require sharper positioning choices, not diminished ambition or reduced cross-functional engagement
• Science credibility, methodologically defensible and payer-ready, is the non-negotiable asset worth protecting under budget pressure
• Content supply chain inefficiency is where late-stage budgets quietly disappear; modular reuse recovers millions before channel strategy is even addressed
• Brand-level execution ownership, supported by centrally provided technology capabilities, resolves the central-versus-local omnichannel tension in practice
• Organizational credibility, built by demonstrating trade-off awareness, not just requesting resources, determines whether leadership funds the final push
This content reflects the personal views of the speakers and is not intended to represent the official position of their respective companies.
There is a predictable moment in a product's life when the organization quietly stops believing in it. Budgets migrate toward the next launch. Senior talent follows. The brand team is told to "protect the base", a phrase that, in practice, means do less, expect less, and prepare the exit narrative. The molecule still has patients to reach, payers to persuade, and science to generate. But institutionally, it has been written off.
The session at Reuters Events: Pharma USA challenged that posture directly. Moderated by Evan Reddick, Senior Director, Medical Head of Leukemia at Takeda, the panel assembled panelists who have run late life cycle brands not as managed decline exercises but as active commercial problems requiring the same cross-functional discipline as any launch. What emerged was less a best-practices list than a coherent operating philosophy: mature brands fail not because the market turns against them, but because the teams managing them stop making deliberate choices.
The Cross-Functional Team Cannot Be a Late Arrival
The assumption that integrated brand teams are a launch-phase construct is exactly the hypothesis that accelerates a mature brand's irrelevance. Elizabeth Arnold, Vice President and Brand Lead at Bristol Myers Squibb, was direct: "Brand teams need to consistently and constantly work together across the lifecycle of the brand." At BMS, that integration starts in pre-launch and extends through loss of exclusivity, with functions rotating in and out but the core structure intact. Organizations treating cross-functional alignment as a launch luxury are building the conditions for late-stage drift before the product ever matures.
What holds those teams together when the external environment shifts, new competitive entrants, evolving guidelines, contracting access, is not a static strategy document. It is shared clarity on two things: the unmet need the product addresses and the patients it serves. Arnold described these as the anchor that keeps positioning coherent even when everything else changes. When a brand team loses sight of those two elements, repositioning exercises become internal politics rather than market-driven decisions.
The speed argument matters here too. Arnold noted that AI will accelerate many execution tasks, content generation, data synthesis, field signal aggregation. But speed tools applied to a disorganized team produce faster noise. "Setting up a process of that constant collaboration and communication is what's needed to help you pre-build the process to enable you to act with speed." The organizational infrastructure has to exist before the moment of required agility arrives, not be constructed during it.
Chris Edmonds, Global Price and Market Access Director at AstraZeneca, brought the access dimension into the same frame. From AstraZeneca's perspective, market access is not a function that activates near reimbursement review. It operates from business development concept through loss of exclusivity. That continuity matters because the evidence payers accept, hard endpoints, indirect comparisons, economic modeling, cannot be assembled retroactively. "What underpins that and is non-negotiable is actually that what we're producing is methodologically correct, it's robust, it's credible, and we can defend it in any way that we have to in front of any organization." Evidence credibility, built over years, is the asset that sustains access when competitive pressure mounts. Teams that deprioritize access involvement during the growth phase typically discover this too late.
Positioning Is Not Fixed. Science Changes It.
The misconception that brand positioning is established at launch and maintained through the product's life is not just strategically wrong, it actively prevents the pivots that late life cycle brands require. Arnold was explicit: positioning can evolve as the marketplace shifts. The unmet need and patient population remain stable. The competitive framing, the data set, the guideline citations, all of it is subject to revision.
What makes that revision possible rather than disruptive is the process architecture the team builds in advance. Arnold described creating a task force specifically to mine existing data sources for new claims, to interrogate real world evidence for strategic support, and to work closely with legal and compliance, not to identify limits, but to identify what could be said in support of the new direction. The task force model distributes the analytical work across functions rather than centralizing it in the marketing team, which typically lacks the clinical depth to evaluate what the data actually supports.
Edmonds pushed this further, arguing that AstraZeneca does not simply respond to science evolution, it actively drives it. "We can be at the forefront of those changes. We can develop the science, we can develop stories, we can develop evidence to actually move and pivot the market as we need to." That means designing trials specifically to shift guidelines, speaking to payers and patients before the evidence is generated rather than after, and continuing that evidence generation deep into the product's life cycle. "We can carry on doing this right up to six, seven, eight years in and still make those changes as we get towards the end of life." The ceiling on late-stage scientific investment is not regulatory approval. It is the team's willingness to keep investing intellectual resources in a product the organization has mentally retired.
Reddick framed the organizational dimension precisely: "Change in the face of science evolution is not failure, it's maturity." The external communication of that reframe, to cross-functional counterparts, to leadership, to the field, is as important as the internal decision to make it. Brand teams that apologize for pivoting signal that the original strategy was wrong. Brand teams that communicate pivots as evidence-driven maturation signal competence, and that distinction shapes how much latitude leadership grants for the next change.
On the omnichannel side, Nataliya Andreychuk, CEO and Co-Founder of Viseven, identified a structural problem that compounds positioning changes: content supply chain latency. When the science shifts, the brand's communication infrastructure has to shift with it, and the content supply chain, with its MLR review cycles and production dependencies, is routinely the rate-limiting step. The answer, she argued, is not to invest in faster channels but to accelerate the upstream process: modular content architecture, AI-assisted derivative creation, and review workflows designed for iteration rather than one-time approval. Channel strategy is irrelevant if the approved content is six weeks behind the science.
Discover more on this topic at Pharma Customer Engagement USA 2026 (October 27-28, Philadelphia) - where commercial, marketing, medical, data and AI pioneers converge. Explore the agenda here.
Budget Cuts Reveal What the Team Actually Believes
The late life cycle budget conversation is where organizational rhetoric meets operational reality. When funding contracts, brand teams discover whether their cross-functional relationships are durable or merely convenient. Reddick named the dynamic plainly: "When you give us lower budgets, you're not giving us less so that we can do more. You're buying the lack of tactics." That framing, strategic narrowing as a deliberate choice rather than a resource failure, separates teams that fight for every dollar and lose credibility from teams that articulate trade-offs and earn the right to make them.
Arnold's approach to constrained budgets was instructive in its specificity. Her team chose to invest in positioning and messaging and explicitly chose not to invest in new campaigns, mining existing creative assets instead. They identified high-concentration geographies and accepted white space in low-potential territories. They activated patient advocacy channels rather than paid media. These were not default austerity measures. They were choices made against a clear view of where the business was actually coming from. "You have to know your business, where your business is coming from and why." Without that clarity, budget reduction becomes indiscriminate cost-cutting. With it, it becomes strategic narrowing.
The credibility dynamic Arnold described deserves attention. When her leadership team asked all brands to contribute to a shared enterprise need, she brought $200,000 from what she characterized as a shoestring budget while peer brands with larger allocations contributed millions. The organizational effect was not embarrassment, it was credibility. Demonstrating enterprise-mindedness when it costs something builds the relational capital that funds the next ask. Brand leads who protect every late-stage dollar and resist enterprise reallocation requests tend to find their appeals for incremental investment receive a cooler reception.
Edmonds described AstraZeneca's equivalent discipline in access: "We tend to cut the peripheral work. We don't cut the engine room." The engine room, economic modeling, real world evidence design, value story maintenance, continues regardless of budget pressure because it sustains payer access and pricing integrity. Cutting it to preserve promotional spend is a trade-off that typically looks acceptable in year one and catastrophic in year three.
Andreychuk argued that the content supply chain is where late-stage teams consistently leave money on the table. Not millions from cutting campaigns, but millions from failing to reuse approved content that already exists. Modular content architecture and AI-enabled recognition tools can surface reusable assets that brand teams would otherwise recreate from scratch. Those savings can fund the targeted scientific or evidence investment that extends the brand's competitive relevance, which means the content infrastructure question is not operational housekeeping. It is a funding decision in disguise.
Followership, Not Compliance, Is the Late-Stage Leadership Test
The operational recommendations from this session are coherent and actionable. But they rest on a leadership condition that is harder to engineer: genuine team belief in the strategy. Arnold's closing observation was the most diagnostic of the session. "Are your teams executing your strategy just because you told them to? Or because they truly believe in it?" The question matters more in late life cycle than at launch because the organizational gravity is working against the brand. Resources are declining. Attention is elsewhere. Team members with options are the most likely to redirect their energy toward newer assets.
Brand leads who rely on positional authority to drive late-stage execution get compliance, teams that complete assigned tactics without the initiative that makes them effective. Reddick articulated the alternative: a shared vision compelling enough that team members act autonomously in service of it. "If they believe in that shared future, they're going to take the next right action. Even when they're in a vacuum themselves."
That kind of followership is not generated by strategy documents or alignment workshops. It emerges from leaders who are specific about where they are going, honest about the trade-offs they are making, and credible enough, with leadership above and with their own team, that the direction feels worth following. Arnold put it plainly: "Actually working on a mature product in my mind is way more energizing, fun, exciting because you have a plethora of data at your fingertips." That orientation, treating late life cycle as an analytical and creative opportunity rather than a holding pattern, is what separates teams that extract remaining value from brands that still have it to give.
The organizations treating late life cycle management as an execution problem, a resource allocation and channel optimization challenge, are solving the wrong problem. The execution tools exist: modular content infrastructure, real world evidence design, payer-ready economic models, AI-assisted field signal aggregation. What determines whether those tools produce durable growth or managed decline is whether the brand team is led by someone who has decided the brand is still worth fighting for, and whether that conviction has become specific enough, and credible enough, to be contagious. In pharma's late-stage commercial environment, that is the capability that is hardest to replicate and most worth building.
To get you highlights of Pharma USA 2026 faster, we are using generative AI technology to summarise the transcripts of the sessions. If you have any feedback about the summary, please contact lucy.fisher@thomsonreuters.com.
Discover more on this topic at Pharma Customer Engagement USA 2026 (October 27-28, Philadelphia) - where commercial, marketing, medical, data and AI pioneers converge. Explore the agenda here.
